What is semaglutide, how well does it work, and how does it compare to tirzepatide?

The short answer

Semaglutide is the most established GLP-1 receptor agonist — sold as Ozempic and Rybelsus for diabetes and Wegovy for obesity — with the deepest evidence base in the class, including the landmark SELECT cardiovascular-outcomes trial. It delivers roughly 15% average weight loss, less than tirzepatide head-to-head, but leads on proven heart-protection, track record, and an oral option.

Evidence tier: 1–2 for the core efficacy and cardiovascular data (STEP and SELECT are large randomized trials). Safety framing is the established class profile. This is education, not medical advice — semaglutide is a prescription medicine and dosing belongs with your clinician.

The key points:

• The most established option — longest track record and deepest evidence in the class
• Proven cardiovascular benefit — SELECT showed a 20% reduction in major cardiac events
• ~15% average weight loss — strong, but less than tirzepatide head-to-head
• Oral and injectable forms — the only GLP-1 with an approved tablet (Rybelsus)

This is a deep dive within our GLP-1 complete guide; compare it directly with our tirzepatide deep dive.

What semaglutide actually is

Evidence tier: 2 — established pharmacology.

Semaglutide is a single GLP-1 receptor agonist — it mimics the gut hormone GLP-1, which slows gastric emptying, increases satiety, and improves glucose-dependent insulin secretion. Unlike tirzepatide's dual GIP/GLP-1 action, semaglutide works through the one receptor, and it was the molecule that turned this drug class from a useful diabetes tool into a cultural and metabolic phenomenon. It's sold under three brand names across two indications: Ozempic (injectable, type 2 diabetes), Wegovy (injectable, obesity), and Rybelsus (oral tablet, diabetes), all from Novo Nordisk.

The injectable forms are dosed once weekly; Rybelsus is a daily tablet with specific administration rules (taken on an empty stomach with a small sip of water, then waiting before eating) because oral peptide absorption is finicky. That oral option is genuinely distinctive — semaglutide is the only GLP-1 with an approved pill — though the oral dose delivers somewhat less weight effect than the injectable. For the structured entity summary and dosing card, see our semaglutide peptide page.

How much weight do people lose?

Evidence tier: 1 — pivotal randomized trial.

In STEP-1, the pivotal 68-week obesity trial, semaglutide 2.4 mg produced a mean weight reduction of about 15%, versus roughly 2.4% on placebo (Wilding 2021). That was a step-change when it landed — the largest weight loss from a medication at the time — and it remains a strong, clinically meaningful result, with many participants losing 10–20% of body weight. The loss accrues gradually over months of titration, the same slow-and-steady trajectory seen across the class.

The honest qualifier is the head-to-head comparison: tirzepatide produces more weight loss than semaglutide when the two are tested directly. So semaglutide is no longer the efficacy leader on weight alone. What it offers instead is the deepest evidence base, the longest real-world track record, the cardiovascular-outcomes data below, and the oral option — a different value proposition than "maximum pounds lost." The plateau and maintenance dynamics in our GLP-1 community insights apply to semaglutide directly.

Why does the cardiovascular evidence matter so much?

Evidence tier: 1 — large dedicated outcomes trial.

This is semaglutide's strongest card, and it's worth understanding why it carries weight. In the SELECT trial — 17,604 adults with established cardiovascular disease and overweight/obesity but without diabetes — semaglutide reduced major adverse cardiovascular events (cardiovascular death, heart attack, stroke) by about 20% versus placebo (Lincoff 2023). That's a hard-outcome benefit, not just a weight or lab-marker improvement, and it established that the drug's value extends beyond the scale to actually preventing cardiac events.

This matters because weight loss and improved markers are surrogate endpoints — useful, but not the same as proving fewer heart attacks. SELECT moved semaglutide into the small group of obesity-related interventions with proven outcome benefits, which is why it now carries a cardiovascular indication. For someone whose real risk is cardiac, that distinction can outweigh tirzepatide's larger weight effect. It's the clearest example of why "which drug is better" depends on which goal — pounds lost or events prevented — matters most for a given person.

Is semaglutide or tirzepatide the right choice?

Evidence tier: 1 — direct head-to-head trials plus outcomes data.

The honest comparison cuts both ways. On weight and glucose, tirzepatide wins the direct head-to-head trials (SURMOUNT-5 and SURPASS-2). On proven cardiovascular outcomes, longest track record, and an oral option, semaglutide currently leads. Neither dominates across every axis, so the decision is genuinely individual: someone optimizing for maximal weight loss leans tirzepatide; someone whose dominant concern is established heart-protection or who wants a pill may lean semaglutide; access, insurance coverage, and tolerability often decide it in practice.

It's also worth noting these aren't permanent verdicts — tirzepatide's own cardiovascular-outcomes data is maturing, and the comparison may tighten. The full side-by-side, including the rest of the class and the pipeline, is in our GLP-1 complete guide, and the tirzepatide-side view is in the tirzepatide deep dive. The unhelpful framing is "X is just better" — the useful one is matching the drug to the goal.

What are the side effects?

Evidence tier: 1–2 — consistent across the trial program.

Semaglutide's side effects are the class-typical GI cluster: nausea, diarrhea, constipation, vomiting, and reduced appetite, worst during dose escalation and usually settling as the body adapts. The slow titration exists precisely to limit these, and rushing it predictably makes them worse. Our GLP-1 side-effects guide covers the management playbook — meal timing, hydration, fiber, and when to hold a dose — and it applies to semaglutide directly.

The class-level cautions apply as well: a boxed warning for thyroid C-cell tumors (contraindicated with a personal/family history of medullary thyroid carcinoma or MEN 2), pancreatitis and gallbladder signals, and dehydration-related kidney risk if GI effects are severe. As with the rest of the class, lean-mass loss accompanies large weight loss and is mitigated by protein and resistance training, and discontinuation commonly leads to regain unless other changes hold — semaglutide treats a chronic condition rather than curing it.

A practical note specific to semaglutide's long track record: because it's been in wide real-world use longer than tirzepatide, the patterns around tolerability are well characterized. Most people who struggle do so during the first weeks and around each dose increase, and most of those who push through the early GI rough patch at a slow titration end up tolerating it well. That's not a reason to minimize the side effects — they're real and occasionally treatment-limiting — but it does mean the early difficulty is usually the hardest part rather than a permanent state, and that a too-fast escalation is the single most avoidable cause of a bad experience.

What about women and pregnancy?

Evidence tier: 2 — reproductive considerations grounded in class data.

Semaglutide carries the same reproductive rules as the class. It must be stopped before a planned pregnancy, and because of its long half-life the guidance is to discontinue at least about two months ahead with adequate washout; pregnancy or the intention to conceive is itself a reason to stop. Restored ovulation from weight loss can also lead to unplanned pregnancy — the fertility paradox we cover in GLP-1s for women: PCOS and fertility — so contraception is an active decision for women of reproductive age, not an assumption carried over from a previous cycle pattern.

Semaglutide has been studied specifically in women with PCOS, where it improves weight, insulin resistance, and often menstrual regularity, making it a genuine women-specific use case within the obesity-and-metabolic picture. As with tirzepatide, this reproductive layer is exactly the kind of drug-specific detail that the generic "weight-loss shot" framing skips, and it's the part most worth getting right.

So who is semaglutide for?

Evidence tier: 2–3 — synthesis into practical guidance.

Pulling it together: semaglutide is the established, well-evidenced choice — strong weight loss (~15%), proven cardiovascular benefit, the longest track record, and the only oral option in the class. It's a particularly compelling choice for someone whose risk profile is cardiac, who values the depth of evidence, or who wants a tablet rather than an injection. The GI side effects and class cautions are the same as the rest of the category and are managed the same way, under clinician supervision.

Where tirzepatide has the edge is raw weight-loss efficacy, so someone optimizing purely for maximal loss may prefer it. The reasonable conclusion is that semaglutide is the more established all-rounder and tirzepatide the efficacy leader, and the right pick depends on goals, tolerability, access, and which evidence matters most — a decision to make with a clinician, embedded in a plan that protects muscle and accounts for the long term.

Limitations

This is educational content, not medical advice.

• Semaglutide is a prescription medicine — dosing, titration, and monitoring belong with a clinician.
• Trial averages aren't individual guarantees — real-world results vary with adherence and lifestyle.
• Tirzepatide produces more weight loss in direct head-to-head trials.
• Class cautions apply in full — thyroid C-cell warning, pancreatitis/gallbladder, lean-mass loss.
• Pregnancy requires a planned pre-conception stop with adequate washout.
• Compounded/gray-market versions add sourcing risk — verify via Finnrick.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

Semaglutide is the most established GLP-1 — Ozempic, Wegovy, and the oral Rybelsus — with the deepest evidence in the class, roughly 15% average weight loss, and, crucially, the SELECT trial's proven ~20% reduction in major cardiac events. It loses the weight-loss head-to-head to tirzepatide but leads on cardiovascular-outcome evidence, track record, and the only approved pill. The side-effect profile and class cautions are category-standard and clinician-managed. The choice between the two is individual: match the drug to whether your dominant goal is maximal weight loss or proven heart-protection.

Related on this site

• GLP-1 complete guide (2026)
• Tirzepatide deep dive (2026)
• GLP-1 side effects and how to manage them
• GLP-1s for women: PCOS, fertility, and cycle effects
• GLP-1 community insights (2026)
• Semaglutide peptide page
• Our evidence-tier framework

References

• Wilding JPH, Batterham RL, Calanna S, et al. 2021. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 384(11):989-1002. PMID 33567185 — pivotal obesity efficacy.
• Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. 2023. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 389(24):2221-2232. PMID 37952131 — landmark CV-outcomes trial.
• Aronne LJ, et al. 2025. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. PMID 40353578 — head-to-head weight-loss comparison.
• Frías JP, Davies MJ, Rosenstock J, et al. 2021. Tirzepatide versus semaglutide once weekly in type 2 diabetes (SURPASS-2). N Engl J Med. 385(6):503-515. PMID 34170647 — head-to-head diabetes comparison.